114 A.E. Gilliam and A.C. GilliamWhen linear morphea occurs on the upper face most notably the paramedian forehead, it is often called en coup de sabre(ECDS)(Fig. 12.1c, d). When it involves the lower face or produces hemifacial atrophy of deeper tissues, it is often called Parry-Romberg syndrome (Fig. 12.1e, f). Whether these conditions are a spectrum of the same disorder or are two distinct entitieshas been a subject of considerable debate, but recent literature suggests that they are on the same spectrum of disease .Epidemiology of MorpheaMorphea is diagnosed more often in whites and females than in individuals of color or in males. The disorder occurs pre-dominantly in young individuals and children with an incidence of 0.4–1 per 100,000 individuals or 25 cases per 1 millionindividuals [13, 17–24]. There is a female: male ratio of 2–3.1 [19, 21]. Morphea is approximately 0.2% of the patientsreferred to a general pediatric dermatology clinic . In general, guttate or plaque-type morphea is more common in adults,and linear morphea is more common in children, with the highest incidence in young white girls.Clinical features of morphea. The clinical appearance of morphea is a puzzle itself – plaques of indurated skin are foundimmediately adjacent to normal skin without induration. Genetic factors surely play a role in the clinical appearance ofmorphea, particularly the linear variants which often follow Blaschko’s lines [7, 25]. Blaschko’s lines are different fromdermatomal skin patterns and are thought to represent embryonic pathways of skin cell development. They reflect geneticTable 12.1 Classiﬁcation of morpheaType Types of lesions Location IncidencePlaque types of morphea Trunk 37% of pediatric morpheapopulation – Circumscribed PlaqueTypeOval or round circumscribed areas ofinduration sometimes with associateddyspigmentation or a violaceous (i.e.“lilac”) border (Fig. 12.1a)Trunk Most common type ofmorphea in adults – Guttate Small (<1 cm) superficial pale plaques Neck and upper trunk – Keloidal/Nodular Nodules of dense sclerosis, typicallyassociated with plaque-type morpheaTrunk Rare – Atrophoderma of Pasiniand PieriniHyperpigmented depressed plaques, noobvious induration (Fig. 12.3a)Trunk, often lower back, innerthigh, axillaeRare – Bullous – Tense subepidermal bullae develop overplaques of typical morpheaTrunk RareRare [71, 83, 169, 170]– Superficial – Involves superficial dermis onlyGeneralized Confluent plaques, hypo- andhyperpigmented (Fig. 12.1b)Three or more anatomicallocations, covering morethan 30% body surface area9% of pediatric morpheapopulation Linear types of morphea Face and extremities 51.4% of pediatric morpheapopulation – en coup de sabre(Frontoparietal linearmorphea)Linear depression with atrophy(Fig. 12.1c, d)Unilateral , scalp and upperface, paramedial lesionsmore common than median17% of pediatric morpheapopulation – Parry-Rombergsyndrome (progressivehemifacial atrophy)Segmental linear deep plaques involvingsubcutaneous fat, muscle and bone; deepatrophy and sclerosis (Fig. 12.1e, f)Unilateral, face 2% of pediatric morpheapopulation – Linear (nonfacial) Discrete, indurated linear bands ofsclerosis of skin often associated withdyspigmentation (Fig. 12.2a–d)Extremities>Trunk, can followBlaschko lines32% of pediatric morpheapopulation Deep morphea/morpheaprofundaPoorly circumscribed bound down scleroticplaques involving fascia, “cobblestone”surface, often hyperpigmentedSymmetric 4% of pediatric morpheapopulation [12, 21,141, 171]– Eosinophilic fasciitis(Shulman syndrome)Deep indurated plaques, onset as localizedpain and edemaExtremities more common thantrunkRare [12, 13, 141, 172–174]– Pansclerotic disablingmorpheaGeneralized full thickness sclerosisextending from dermis to bone, withfixation to underlying structures(Fig. 12.3b)Extremities, progressing to restof body, sparing fingertipsand toes, “tank top sign”Rare [12, 141, 175]
11512 Localized Forms of Sclerodermamosaicism that is invisible in the normal individual and apparent in some of the genodermatoses such as epidermal nevus,incontinentia pigmenti and Goltz syndrome, and in acquired skin disorders such as linear lichen planus and lichen striatus.Cutaneous mosaicism can involve mutations in either keratinocytes (epidermal nevus, incontinentia pigmenti) and/or fibro-blasts (focal dermal hypoplasia or Goltz syndrome). In linear morphea, presumably the fibroblasts in the affected area haveFig. 12.1 (a) Plaque type morphea: Young adult man with an indurated flesh colored plaque with a faintly erythematous border on the right chest.(b) Generalized morphea: 9-year-old girl with numerous sclerotic pink and ivory colored plaques on the trunk. (c, d) En Coup De Sabre (linearmorphea of the face): 15-year-old girl with several year history of progressive linear depressions on her forehead (d). The appearance of the earlyinflammatory plaque without significant sclerosis in (c) demonstrates how morphea can be misdiagnosed as a vascular lesion. (d) shows thesclerosis after 4 years. (e, f) Parry-Romberg Syndrome (linear morphea of the face): 4-year-old girl with progressive linear depressions on herlower face (f) involving the chin, mandible, neck and tongue (e)
116 A.E. Gilliam and A.C. Gilliama different genetic footprint than adjacent normal skin. The mutations are not known, but extensive molecular evaluation ofscleroderma fibroblast genes may ultimately provide clues to similar genetic alterations in affected skin in morphea.Clinical course of morphea. Disease activity of morphea, particularly plaque type, can resolve in 3–5 years, but reactivationmay occur . The course is variable depending on the subtype. Linear morphea tends to be more chronic. Overall, thecourse is benign, with survival no different from the general population . There is significant morbidity associated withthe linear forms however, including joint contractures, limb length and size discrepancy, arthritis/arthralgias, and neurologic/ophthalmologic consequences when morphea occurs on the scalp and face (see Morbidity below). Other symptoms includedysphagia and dyspnea . The main complaints for the most common form, plaque-type morphea, are skin tightness,itching, and unfavorable cosmetic appearance.Fig. 12.2 (a) Linear morphea of the extremity: 12-year-old girl with sclerosis, dyspigmentation and asymmetric growth of the right lower extrem-ity after onset of linear morphea many years ago. (b–d) Linear morphea of the extremity associated with disabling contractures: Several examplesof contractures on foot and hands in children with longstanding linear morphea
11712 Localized Forms of SclerodermaMorbidity in morphea. Quality of life assessments show that individuals with morphea have better outcomes than those withdisabling severe atopic dermatitis, with the exception of the more severe forms of morphea affecting face and limbs .A variety of morbidities are reported more frequently in the linear  and generalized or mixed subtypes  of mor-phea. The more commonly associated complications include musculoskeletal and deep soft tissue abnormalities, neurologic/ophthalmologic problems, and other extracutaneous complications including gastrointestinal, vascular, pulmonary, renal andcardiac problems. Malignancy is a rare associated morbidity. Few systematic studies have been performed because of therare frequency of morphea and even more rare co-existing morbidities .• Musculoskeletal and soft tissue complications. The most common extracutaneous finding in morphea patients is arthritis/arthralgias, which has been reported in 12% of pediatric patients with morphea . Both articular and soft tissue/bonyabnormalities are typically associated with linear morphea. Other musculoskeletal complications include joint swelling,myalgia, and limb contractures [8, 11] (Figs. 12.2b–d and 12.3b). Spontaneous fractures , unexplained muscle atro-phy , hemiatrophy  and osteomyelitis  have also been reported. Morphea can be preceded by unexplainedskin edema [32, 33] or atrophy . One case of linear morphea presented as a neuromuscular disorder with muscleatrophy, weakness and loss of arm function . Individuals with facial linear morphea can have dental abnormalities and even ipsilateral tongue hypoplasia (Fig. 12.1e).• Neurologic complications. Neurologic involvement was reported in 4% of pediatric patients with morphea . It is morecommon in patients with linear morphea of the face. Complications include seizures, headache, and peripheral neuropa-thy among others. Intractable partial seizures , epileptic encephalopathy , and status migrainicus  have allbeen reported in association with morphea. Epilepsy can precede the development of en coup de sabre [39, 40]. Localizedepilepsy, often refractory to medications, is the most common complication of linear morphea of the face . Kistgeret al. reviewed 54 patients with craniofacial scleroderma who also had neuroimaging (head CT or MRI) for neurologicalsymptoms. They found some common atypical features on imaging including atrophy, calcifications and T2 hyperintensi-ties. Others have described abnormal MRI results in patients with Parry–Romberg syndrome .• Ophthalmologic complications. Ocular involvement was reported in 2% of pediatric patients with morphea . Ocularinvolvement in morphea is also more common in patients with linear morphea that affects the face although it has alsobeen reported to occur in patients without facial skin lesions . Associated ophthalmologic abnormalities may includeanterior uveitis, episcleritis, glaucoma, xerophthalmia, keratitis and, strabismus.• Other extracutaneous complications. Gastrointestinal involvement, namely esophageal motor function abnormalitiescausing acid reflux and/or dysphagia, has been reported in approximately 2% of pediatric morphea patients . Vascularcomplications including Raynaud’s phenomenon are also reported in about 2% of patients . Pulmonary involvementcan present with dyspnea and is rare. Renal complications include nephritis , unilateral renal artery stenosis andimmunoglobulin M nephropathy . Cardiac complications include pericarditis and arrhythmias due to supraventricularectopic beats and runs . These systemic complications of morphea indicate that disease is not just “skin deep.”• Malignancy. Rare cases of malignancy are reported in morphea lesions, such as squamous cell carcinoma of the lip thatdeveloped in an individual with pansclerotic disabling morphea . The etiology is likely similar to carcinoma develop-ing in chronic venous insufficiency ulcerations and burn scars.Autoimmunity in morphea. Individuals with the variants other than plaque-type morphea can have peripheral eosinophilia andabnormal serologies – the most common are positive antinuclear (ANA) and/or rheumatoid factor, and presence of anti-ssDNAFig. 12.3 (a) Atrophoderma of Pasini and Pierini: Preadolescent girl with several year history of a large plaque and small patches of atrophy onthe lumbar back. The lesions have a sharp drop-off with a “punched out” appearance and are not indurated clinically. (b) Pansclerotic disablingmorphea: Rapid onset of diffuse sclerosis and hyperpigmentation of the hands and arms resulted in contractures of the fingers reminiscent ofsystemic scleroderma in this 13-year-old girl
118 A.E. Gilliam and A.C. Gilliamand antihistone antibodies – which suggest autoimmune disease, but do not reliably correlate with disease activity [21, 46, 47].There are no laboratory tests that confirm the diagnosis of morphea, which is made on clinical and histopathologic criteria.Like other autoimmune diseases such as scleroderma, the autoantibodies are not directly pathogenic, and are likely epiphe-nomena reflecting immune dysfunction.The presence of a positive ANA and serum autoantibodies was studied in a cohort of 72 adult and pediatric patients withlinear morphea . The authors found no differences in ANA-positivity or type of autoantibody between children andadults. Antihistone and anti-dsDNA antibodies tended to be associated with more severe disease in children. Autoantibodytiters do not appear to correlate with disease activity but can reflect the burden of disease.In another study, positive autoantibodies occurred in individuals with morphea with an incidence of 46–80% (ANA), 50%(anti-ssDNA), 47% (anti-histone antibodies),and 26% (rheumatoid factor) . Sato  reported that 46% of individualswith morphea have anti-cardiolipin antibodies and 24% have positive lupus anticoagulant tests. Approximately 16% ofpatients in a small study (n=41) had increased serum antibodies to matrix metalloprotease-1 by ELISA . Elevated serumB-cell activity factor (BAFF) in individuals with morphea is higher compared with normal controls, particular in generalizedmorphea .Positive ANA and body surface area of involvement had prognostic value in a retrospective study of 35 adults and chil-dren with plaque-type (n=15), generalized , linear morphea  and eosinophilic fasciitis. The majority of patients ontreatment improved clinically and by morphometric measurements of skin induration (53%). Failure to improve or stabilizeafter a mean follow-up of 29 months was associated with generalized morphea and/or positive ANA .An interesting but unexplained feature of autoantibodies found in morphea patients is that they are mainly those of lupus,not scleroderma, which morphea resembles clinically and microscopically. Rare cases of morphea with scleroderma autoan-tibodies such as anti-centromere antibodies are described .In a larger study of 245 individuals with morphea that included 123 adults and 122 children, there was a high prevalenceof concomitant autoimmune disease (18%) and familial autoimmune disease (16%). These authors found a strong associa-tion between the generalized and mixed morphea subtypes and markers of a “systemic autoimmune process” which includedhigh frequency of concomitant autoimmune disease, extracutaneous complications, and abnormal serologies (i.e. ANA).They suggested that patients with these subtypes of morphea (generalized and mixed) should be monitored closely for thepresence of systemic and autoimmune disorders and treated with immunosuppressive therapy when appropriate .Similarities and differences between morphea and scleroderma. Scleroderma (systemic sclerosis) occurs mainly in adultwomen and is characterized by not only skin sclerosis, but also visceral sclerosis (lungs, kidneys, and esophagus). Thepresentation of scleroderma is different from morphea. Scleroderma typically begins in acral skin and progresses proxi-mally, often involving the trunk. Patchy involvement as seen in morphea is uncommon. Extensive cutaneous and visceraldisease in scleroderma has significant morbidity and increased mortality.Molecular genetic studies in morphea. Milano et al.  used gene array analysis to establish a genetic “fingerprints” forscleroderma subsets, including morphea, compared with normal controls. They identified 5 significantly different geneexpression change clusters: diffuse-proliferation, inflammatory, limited, and normal-like. Gene expression profiles from3 biopsies of morphea skin fell into the inflammatory category which was characterized by markers for increase in immuneresponse, response to pathogen, humoral defense, lymphocyte proliferation, chemokine binding, chemokine receptor activ-ity, and response to virus. The gene array results overall confirm and further refine the distinct subsets of scleroderma, anddemonstrate that morphea can potentially be differentiated from those subsets at a molecular level.Overlap autoimmune disorders and other skin disorders in morphea. The role of genetics in autoimmune diseases is impor-tant yet incompletely understood, particularly in morphea. There are no specific mutations that are associated with morpheabut familial morphea and morphea in association with other autoimmune disorders occurs, suggesting a genetic predisposi-tion [11, 46, 56, 57]. Some clues to an “autoimmune phenotype” – a genetic predisposition to autoimmune disease – areseen in these familial and overlap forms of connective tissue disease. For instance, of 47,361 individuals with rheumatoidarthritis in a Swedish study, there was a significant risk (SIR2.4) of morphea in their offspring . Morphea can also coex-ist rarely with other autoimmune diseases, most often reported as case studies. These unusual overlap disorders includemorphea variants with other connective tissue and autoimmune diseases such as scleroderma , systemic lupus erythe-matosus [60, 61], rheumatoid arthritis , inflammatory bowel disease , autoimmune thyroid disease [63, 64], vitiligo[63, 65, 66], alopecia areata, Type I diabetes mellitus , antiphospholipid syndrome , necrotizing vasculitis , aswell as mixed types of morphea [16, 69, 70]. Other types of inflammatory skin disorders can also be associated rarely withmorphea such as psoriasis , lichen planopilaris , lichen sclerosis , and lichen striatus . A case of morpheain association with Rosai-Dorfman disease is reported .Histopathology of morphea. Classic morphea can have a different histopathology depending on the stage of development.The histopathologic changes have been divided into indeterminate (early), inflammatory, mixed inflammatory and sclerotic,
11912 Localized Forms of Sclerodermaand sclerotic (late) stage morphea . As expected by definition, increased T-cells are present in the inflammatory stagecompared with normal skin.Like scleroderma, the inflammatory stage of morphea is characterized by dermal edema, and by lymphocytic and histio-•cytic inflammatory cell infiltrates with plasma cells.The later sclerotic stage is characterized by thickened acellular homogenized-appearing collagen bundles at all levels of•dermis, typically seen first in the deep reticular dermis near interface of dermis and fat. The adnexal structures (hair, eccrineglands) are surrounded by dense fibrosis with loss of fat around the eccrine glands in chronic disease (Fig. 12.4a–e).The atrophic stage is characterized by dermal atrophy and eventual disappearance of adnexal structures.•Eosinophilic fasciitis is considered by some to be a deep version of morphea with the fibrotic changes in the deep dermisand fascia, which are thickened and contain hypertrophied collagen bundles. There is typically a dense perivascular inflam-matory cell infiltrate composed of lymphocytes, histiocytes, plasma cells and eosinophils in the fascia.Fig. 12.4 (a) Skin biopsies of morphea have a characteristic “squared off” shape because of the dense dermal sclerosis. There are patchy perivas-cular mononuclear cell infiltrates of lymphocytes, histiocytes and occasional plasma cells, but otherwise the dermis is acellular compared withnormal skin. Flattening and atrophy of the epidermis is associated with underlying sclerosis. Hair follicles and sebaceous glands normally seenin a skin biopsy of hair-bearing skin are absent. (Magnification=2.5×). (b) This specimen shows the characteristic “bottom up” sclerosis that canbe seen in morphea before entire dermis is involved. The sclerotic collagen is in the lower half of dermis, while normal collagen is in the upperhalf. Dense collagen has replaced normal collagen from the arrow down. The left upper corner of the image also shows the edge of an atrophichair follicle. (Magnification=5×). (c, d) Higher power views of the non-sclerotic (c) and sclerotic (d) dermal areas show that the collagen in thesclerotic area has lost the fine fibrillar texture of normal collagen seen in non-sclerotic areas (Magnification=40×). (e) Encasement of adnexalstructures by dense collagen with loss of the fat around eccrine glands is shown. Eventually, atrophy of hair follicles, sebaceous glands, andeccrine glands (arrow) occurs in long-standing morphea. (Magnification=20×)
120 A.E. Gilliam and A.C. GilliamA clinical and pathologic study of 17 patients with atrophoderma of Pasini and Pierini showed similar histopathology inall cases, some of which were compared with unaffected skin in the same individual . There was no atrophy, sclerosis,or entrapment of adnexal structures. The only abnormal finding in elastic tissue stained sections was reduced total numbersof elastic fibers, many of which were fragmented.Elastic fibers in the skin in morphea. [76, 78] Morphea can resemble a scar microscopically; elastic fiber staining withelastic van Gieson histochemistry can be helpful in distinguishing the two entities because elastic fibers are lost in scars butnot in morphea. Walters  describes preservation of elastic fibers in all biopsies of morphea by histochemistry (n=28).There were straightened compressed fibers with parallel orientation between sclerotic collagen bundles in both sclerodermaand morphea which are indistinguishable microscopically.Therefore, histochemistry and immunohistochemistry (see below) are helpful in distinguishing morphea from otherclinical mimics such as scars, hemangiomas, and vitiligo.Immunohistochemical studies of morphea. Investigators have evaluated matrix molecules, dendritic cells and immune cellsin morphea by immunohistochemistry. Not all of these studies used uninvolved skin of the same individual for comparisonunfortunately.CD34 and Factor XIIIa (FXIIIa) in normal skin. CD34 and Factor XIIIa (FXIIIa) immunostaining identifies two differentpopulations of dermal dendritic cells. Both are found in embryonic mesenchyme and persist in adult tissue. CD34 (hematopoi-etic progenitor cell antigen) is a membrane marker for many types of cells including hematopoietic stem cells, endothelialcells, embryonic fibroblasts, and fibrocytes [79, 80]. In normal skin, there are numerous dendritic CD34+ cells with fine pro-cesses scattered among collagen bundles of reticular dermis in a diffuse pattern. These cells are likely fibrocytes, a normalcomponent of skin that function in wound repair . FXIIIa+cells include platelets, megakaryocytes, bone marrow cells,tissue monocyte/macrophages, and dermal dendrocytes, which are found mainly in papillary but not reticular dermis in normalskin. FXIIIa is a protransglutaminase component of the coagulation cascade that is activated by thrombin and calcium to cross-link fibrin in clot formation (“fibrin stabilizing factor”). It also functions to cross-link matrix proteins, including collagen.CD34+ and FXIIIa+cells in the skin in morphea. In scleroderma and morphea, the immunostaining pattern is reversedwhen compared with normal skin. CD34 immunostaining is lost and FXIIIa is gained in the areas of sclerosis [1, 76, 81–83].When fibrocytes become activated, they become CD34-negative smooth muscle actin–positive myofibroblasts and secretecollagen. It is a plausible hypothesis that FXIIIa+tissue macrophages appear in active areas of sclerosis and cross-link thenew collagen synthesized by the now CD34-negative fibrocytes .UVA1 phototherapy for morphea may act by changing the cytokine and stromal microenvironment to favor persistenceand not loss of the CD34 dermal dendritic cells and return to normal collagen synthesis and degradation . In one studyin which CD34 and FXIIIa immunostaining was evaluated after UVA1 phototherapy, the UVA1 was less effective in restor-ing CD34+ dermal dendrocytes in linear (n=2) than in plaque type morphea (n=5). UVA1 also decreases inhibitory Smad7expression in morphea, another possible effect on fibrosis .T-cells and antigen-presenting cells in the skin in morphea. Immunostaining for various immune markers on biopsy speci-mens from morphea patients shows increased numbers of T-cells (CD3+, CD4+, CD8+) and dendritic cells (CD1a+, CD25+,CD57+) compared with normal controls (p<0.05). CD30+ cells were approximately the same in that study . The findingis not surprising — no effort was made to compare with other similar skin diseases such as scar and comparable inflamma-tory disorders, or with uninvolved skin from the same individual to establish specificity of the findings for morphea.Macrophages in the skin in morphea. CD68, CD163 (hemoglobin scavenger receptor), and CD204 (Class A scavenger recep-tor molecule) have high expression on alternatively activated M2 macrophages in morphea . M2 macrophages are impor-tant in the early stages of fibrosis—they have an IL-10 low, IL-23 low, IL10-high phenotype and influence wound repair andsclerosis by releasing TGF-beta. Similar increases in activated macrophages have been reported in systemic sclerosis .Melanocytes in the skin in morphea. Sung et al. demonstrated with immunoperoxidase and immunohistochemical stainingthat there were reduced numbers of melanocytes in the epidermis in 2/3 cases of hypopigmented morphea and 2/4 cases ofnon-hypopigmented morphea compared with 7 matched biopsies of normal skin . The data suggest a complex immuno-phenotype in children with morphea that involves more than dermal changes. These data help to explain the hypopigmenta-tion often seen in morphea clinically (approximately 54%) in a set of 35 children with morphea in a pediatric dermatologyclinic at UCSF .Cytokines and growth factors in the skin in morphea. Most of the in vivo and in vitro work on fibrosis has been done inscleroderma and in cell cultures of scleroderma fibroblasts. Some information is published on morphea from which we canextrapolate a hypothesis for pathophysiology. There are serum and tissue cytokine alterations similar to scleroderma which
12112 Localized Forms of Sclerodermaare associated with morphea that suggest a mechanism for initiation and perpetuation of the fibrotic phenotype. Immunostainingon skin biopsies of the inflammatory phase of morphea shows increased transforming growth factor (TGF)-beta  andinsulin-like growth factor, a mediator of extracellular matrix homeostasis . Increased circulating TGF-beta1, intercellularadhesion molecule −1 (ICAM-1), interleukin-2 (IL-2) IL-4 and IL-6 in patients with morphea may promote increased col-lagen synthesis and fibroblast proliferation [90–92]. These profibrotic Th2 cytokines along with TGF-beta, PDGF, CTGF andmetalloprotease-3 promote the stromal changes of morphea. The immune mediator pathways are complex and not completelyworked out. Cytokine therapy has been proposed and tested in a few clinical trials for morphea but as in scleroderma, obtain-ing appropriate controls and demonstrating efficacy is difficult in a disease which can resolve on its own.Morphea induced by environmental triggers (Table 12.2). The emergence of morphea following exposure to environmentalexposures is intriguing and may provide clues for the pathophysiology of morphea. The triggers fall into the categories ofradiation, drugs, trauma, and infection.Table 12.2 Morphea induced by environmental agentsInduced by Agent Action Clinical ReferencesRadiation X-ray therapy forbreast carcinoma;fluoroscopyRadiation may induceneoantigens that trigger theprofibrotic inflammatorycascadeLate onset erythema and induration,not dose-related, with dermalfibrosis extending beyond theradiation port[93–98, 100,104, 176]Drugs Anti-TNF-alpha agents Biologic immunomodulators,inhibit TNF-alphaBalicatib Cathepsin K inhibitor forosteoporosisClassic morphea plaques in 58-year-old woman, resolved when drugdiscontinuedBleomycin Antibiotic and chemotherapeuticagent that induces DNA strandbreaks, inhibiting DNA repairScleroderma-like skin changes in rareindividualsBromocryptine forpituitary microadenomaand Parkinson’s diseaseDopamine D2 and D3 agonist thatactivates post-synaptic signals.Inhibits prolactin release bypituitary gland57-year-old man with plaque-typemorpheaDocetaxel for breastcarcinomaMicrotubule-stabilizingchemotherapeutic agent, haltsmitosis and allows apoptosisof malignant cellsPlaque-type morphea, begins asedema, involves lower extremitiesand spares hands and feet[105, 179, 180]Ibuprofen Cyclooxygenase inhibitor, blocksprostaglandins which modulateinflammatory pathways20-year-old woman with linearmorphea and en coup de sabrehad positive lymphocyte IFN-gamma release activation test foribuprofen; clinical improvementafter ibuprofen discontinuedl- tryptophan;l-5-hydroxytryptophanplus carbidopa,bromocryptineand clobazam forParkinsons’s diseaseEssential amino acid used forinsomnia, sleep apnea,depression, anxiety; 5-OHtryptophan is a precursor forserotoninUse of l-tryptophan documented ineosinophilia-myalgia syndrome[182, 183]Trauma Vibration Unknown Unilateral generalized morphea in amarble cutterTattoo Trauma to skin known to producemorphea rarelyMorphea-like reaction in red pigmentarea of tattoo in 47-year-oldwomanInjection sitemorpheaMepivacaine HCl,vitamin K, vitaminB12, pentoazocine,aluminum absorbantfor allergy shots;vaccination in infantsPossible vascular injury Several case reports of deep morphea-like sclerosis in injection sites[105, 186–188]Infection Hepatitis B and C Viral activation of immunesystem, including interferonsIndividuals with chronic hepatitisB and C[189–193]Borrelia Possible selective activation ofhyperaggressive autoimmuneT-cells; molecular mimicryAssociated with acrodermatitischronicum atrophicans andmorphea in Europe[115, 116]
122 A.E. Gilliam and A.C. GilliamRadiation- and surgery-induced morphea [93–100]. Morphea at the site of supervoltage therapy for breast carcinoma iswell-described, occurring in approximately 0.2% of women treated for breast cancer from a few months to up to 20 yearsafter the radiation therapy . Another name for the disorder is “radiation port scleroderma”. The association with tamox-ifen therapy in the cases involving the breast is questionable; the controlled studies and statistical analysis have not beendone. Cases of recurrent radiation-induced morphea after a second surgery but no radiation and following cosmetic surgeryalone suggest that the surgery itself may play a role in this variant of morphea [97, 102, 103].Other rare variants of radiation-induced morphea includeExtensive morphea on lower abdomen and upper extremities in a 74-year-old woman with extensive morphea after radio-•therapy to the pelvis for endometrial carcinoma .Morphea following fluoroscopy [• 104]Post-radiation morphea can mimic radiation dermatitis, infection and recurrent breast carcinoma. Differentiating mor-phea from radiation dermatitis depends on both clinical and histopathological features .Radiation injury has dose-related acute erythema and scaling, possibly desquamation, and deep fibrosis in subcutaneous•fat, fascia, and muscle that are confined to the radiation port. Bizarre atypical fibroblasts, hyperpigmentation, dermalatrophy, and telangiectasia are microscopic clues to radiation dermatitis, not morphea.Post-radiation morphea has later onset, erythema and induration that are not dose-related. There is rapidly progressive•predominantly dermal fibrosis that extends beyond the radiation port.The pathophysiology of post-radiation morphea is thought to be neoantigen production by ionizing radiation that triggersthe pro-fibrotic inflammatory cascade . Tamoxifen may induce TGF-beta production and induce fibrosis, but the path-ways are complex and not completely understood.Drug-induced morphea. Drug-induced morphea is rare, and has been reported for a diverse group of medications from anti-epileptics to chemotherapeutic agents (Table 12.2). In these case reports, the proof of concept was the partial or completeresolution of morphea after stopping the medication . Profibrotic agents associated with drug-induced morphea arebleomycin, peplomycin, dopaminergic drugs and beta-blocking agents . Several agents (i.e. pentazocine) can causedirect vascular injury and dermal sclerosis, likely the etiology for the injection site type of morphea.Other common themes include interference with signaling pathways [anti-tumor necrosis factor (TNF) alpha agents andbalicatab]. Interferons have been used for therapy of morphea with paradoxical results. Intralesional interferon-gamma wasreported to be successful for linear morphea in case reports  and interferon-gamma was used successfully for ocularsymptoms of en coup de sabre , presumably because interferon inhibits fibroblast growth and collagen synthesis invitro. However, the systemic in vivo effects can be quite different from local effects. Interferon-beta therapy for multiplesclerosis may be a trigger for development of morphea in a subset of individuals, suggesting a genetic predisposition tofibrosing disease . Interferon-alpha therapy for myeloproliferative disorders or chronic hepatitis in several case reportsresulted in worsening or new onset of scleroderma and morphea, rather than improvement [109–111]. These findingsemphasize the complex immunological networks in morphea and scleroderma. It is not always possible to translate in vitroexperiments to in vivo therapy with biologic agents which can have many different functions in vivo.Trauma. In a study of 26 patients with severe juvenile localized scleroderma, four (15% ) reported a history of trauma tothe area and one had a history of dental extraction ipsilateral to the area in which morphea developed . Another possibletrigger is vibration, thought to be a factor in a case report of a marble cutter who held an electric tool in his left hand anddeveloped extensive sharply demarcated unilateral morphea on the ipsilateral side . He had no lung disease to suggestsilica-induced scleroderma. Other instances of fibrosing disease, i.e. sclerodactyly, due to vibration in chainsaw users, metalworkers, forestry workers, miners, quarry drillers and stone-carvers have been reported. There are many examples in theliterature of injection site morphea, including onset of morphea at the site of vaccinations as well as at the site of an insulinpump placement (observed by these authors) (Table 12.2).Infection. Borrelia infection is a confounding factor in European studies of morphea because a small percentage (7%) ofindividuals with morphea has positive Borrelia titers . It is not clear if Borrelia plays a role in pathophysiology of mor-phea or if this is a coincidental finding because Borrelia exposure is common in Europe [113–116]. Acrodermatitis chroni-cus atrophicans is thought to be an atrophic variant of morphea induced by Borrelia infection .Pathophysiology of morphea. The reason for the heterogeneity of the morphea variants is a fascinating puzzle yet to besolved. Also fascinating are the rare forms of morphea typically in adults associated with various environmental triggerssuch as radiation, drugs, trauma, and injected substances, among others (Table 12.2). The variety of disease forms and pos-sible etiologies in morphea suggests that there are many different pathways to skin fibrosis. Hypotheses include autoimmune
12312 Localized Forms of Sclerodermaactivation, vascular alterations and injury, and abnormal collagen metabolism. The pathophysiology of infection-inducedmorphea such as hepatitis and Borrelia infection may be due to activation of hyperaggressive T-cells in response to infection,release of interferons, and by molecular mimicry . There are no hard data for these hypotheses however.Because of its uncommon incidence predominantly in children and generally benign course, basic laboratory investiga-tion into the pathophysiology of morphea has lagged behind that for scleroderma. We assume that because morphearesembles scleroderma microscopically, it has the same underlying pathophysiology – i.e. alterations in TGF-beta, plateletderived growth factor (PDGF) and other cytokine and growth factor microenvironments, and alterations in pathways ofmatrix production and collagen metabolism. A combination of these changes could lead to excessive production of normalcollagen. As in scleroderma, triggers for disease may include endothelial cell injury and activation of an inflammatorymediator cascade . The experimental data to support these hypotheses for morphea are not available to date, however,and there is no animal model for morphea.Practical Guidelines for Assessment and Management of Morphea, OverviewClinical evaluation, although problematic, is still the gold standard for morphea diagnosis and assessment. The classic“active” lesion is a well-circumscribed indurated plaque with a violaceous border, which indicates ongoing inflammation.Disease activity can also be associated with increased warmth of skin lesions as well as increasing size of the plaque/s. Meantime to diagnosis was 1.2 years in a retrospective study of 136 children with morphea . The delay was mainly due tolack of recognition of morphea by primary care physicians. Morphea can rarely present with fever, arthralgias, and lymph-adenopathy before the development of obvious sclerosis.Management of morphea can be challenging because reliable and widely accepted measures for monitoring diseaseactivity in morphea are not available. Clinical evaluation and laboratory testing are not reliable methods for detecting andfollowing disease activity in morphea. Making decisions about choice of initial therapies, intervening with more aggres-sive therapy, and monitoring effectiveness of therapy are problematic. Development of therapeutic clinical trials andoutcome studies depends on objective and validated measures to monitor disease activity, a challenge in the study ofmorphea.Assessment of morphea [48, 119, 120]. Unlike scleroderma, where a combination of accepted clinical indices based on skinthickening and sclerotic changes are used to score disease severity , scoring severity of disease in morphea with patchylocalized cutaneous involvement is more challenging. Many physicians use parameters such as degree of warmth and rela-tive “softness” of the skin to monitor disease course. These methods are subjective however, and quantifiable methods arepreferable. The following non-invasive methods do not expose the patient to the risk of poor healing, scarring and the poten-tial for wound infection after skin biopsy; they allow quantifiable and sequential assessment.Quantifiable Clinical Assessment• Skin scores. A modified skin score (MSS) has been used for morphea, but the MSS is only reliable for extensive skinlesions and is not designed to detect subtle increases in size of skin lesions [122, 123]. Another clinical tool to assessmorbidity in morphea, the Localized Scleroderma Skin Damage Index, involves calculation of scores for three parame-ters of cutaneous damage: dermal atrophy, subcutaneous atrophy and dyspigmentation measured at 19 anatomic sites. These scores correlate well with the Physician Assessment of Global Disease Damage, a more general tool fordisease in general. However, the scoring system is not applicable to isolated localized lesions.• Dermoscopy shows accentuated fibrotic tracts crossed by spreading telangiectasia centrally with an obvious erythema-tous border peripherally in plaque type morphea [2, 124]. Like dermoscopy of pigmented cutaneous lesions, dermoscopyrequires a level of experience with the dermatoscope.Skin thickness can be measured and followed over time using a• durometer .A computerized method for measuring and following of circumscribed lesions of morphea over time consists of delineat-•ing the morphea plaque with transparent adhesive film, transferring to cardboard, and calculating the area of the plaquewith specific software . This method includes body surface area (BSA) in its calculations of rate of change overtime. Although promising, this method for monitoring disease activity has not yet been evaluated prospectively and isnot widely available.
124 A.E. Gilliam and A.C. GilliamImaging Methods• Ultrasound [126–129]. The most reliable assessment uses 20–25 MHz ultrasound (US). Ultrasound at 10–15 MHz –which is more readily available in the Unites States – is also useful [126, 127]. This modality appears more helpful inmaking the diagnosis of morphea, rather than for monitoring disease activity . However, ultrasound assessment isoperator-dependent and lacks standardization.• Magnetic resonance imaging (MRI ). Although the MRI findings in morphea can overlap with other soft tissueabnormalities such as fibromatoses and myofibromatoses, there are some pathognomic features of morphea which dis-tinguish it from those entities. MRI allows evaluation of depth of infiltration and sequential analysis of diseaseactivity.• Infrared thermography for detection of disease activity via blood flow changes in early morphea is also an exciting newarea of investigation . Infrared thermography uses an infrared camera and Thermosoft software. It is comparablewith clinical assessment unless severe atrophy of skin and fat has occurred [23, 131, 132]. In these locations, there arerelatively high false positive rates for clinically inactive lesions, especially those located on the face and scalp. This isattributed to increased skin heat conduction because of the relatively thinner skin and decreased density of subcutaneousfat in these areas. Therefore, thermography is less appealing as a reliable tool for monitoring disease activity not onlybecause it appears to be useful only in certain clinical contexts but also because it is not widely available. The combina-tion of infrared thermography and laser Doppler flowmetry – which measures the cutaneous microcirculation – is moreeffective in these cases [7, 128, 133].All of these methods have not been prospectively evaluated to date, and most are not widely available.•TherapyTreatment of morphea. Morphea is difficult to treat ---and well-controlled clinical trials are difficult to carry out because ofthe low incidence of morphea, the lack of objective measures for monitoring disease activity, and the tendency for morpheato regress spontaneously. In children with morphea, clinicians are reluctant to treat aggressively with immune modulators.Because of the morbidities in morphea (see above), early treatment is recommended, particularly of the inflammatory stageof disease . The goal is to limit damage and prevent the sequelae of cutaneous fibrosis.There are several different strategies for therapy that are based on hypotheses of triggers for morphea:Altering the inflammatory immune cascade: topical corticosteroids, topical calcineurin inhibitors, imiquimod, vitamin D•analogues (calcitriol and calcipotriol), methotrexate, mycophenolate mofetil and UVA1 phototherapy all alter thecytokine and growth factor microenvironment of skin. The new biologics also function to change the cutaneous immuneenvironment.Altering the vascular microenvironment: bosetan, an endothelin receptor antagonist, likely functions by altering vascular•resistance.Altering the extracellular matrix homeostasis:• d-penicillamine inhibits cross-linking of collagen.The most common topical and systemic therapies reported during the 1980s and 1990s are listed in Table 12.3 [15, 47, 129,135–139].Topical therapy.  (Table 12.3) The mainstay of morphea treatment is topical corticosteroids and more recently, topicalvitamin D analogues, calcineurin inhibitors and imiquimod.Phototherapy. Phototherapy has been a great advance in morphea therapy because it is tolerated well and does not put thepatient at risk for the potential side effects associated with systemic treatment with oral immunomodulators .Penetration of the skin by ultraviolet light depends on the wavelength. UVB is not as effective as UVA because it penetratesthrough only epidermis and superficial dermis. Long wavelength UVA (UVA-1) is not absorbed as effectively by melanin,and the longer wavelength allows the deepest penetration of skin. Thus UVA-1 phototherapy has been used successfully fordeep morphea and eosinophilic fasciitis [141, 142]. Other forms of phototherapy used for morphea include topical psoralenwith ultraviolet light (PUVA), narrow band ultraviolet B (NbUVB) therapy, and photodynamic therapy which uses light inthe visible range [143, 144]. Changes in the cytokine and growth factor microenvironment, induction of metalloproteases,and apoptosis of lymphocytes may all help to explain the beneficial effects of phototherapy in morphea. Side effects of
12512 Localized Forms of SclerodermaTable 12.3 Therapies for morpheaTopical therapiesAgent Action Dose Adverse effects ReferencesTopical corticosteroids Changes cytokinemicroenvironment of skin,inhibits T cellsStrength and dose dependson location on bodyCutaneous atrophyand telangiectasia;potential skinirritation forsystemic absorption;occasionally contactdermatitis[13, 195]Topical calcipotrieneointment(1, 25-dihydroxyvitaminD3)Active metabolite of vitamin D3,affects fibroblast proliferationand function and inhibitsinflammatory mediators0.005% ointment underocclusion twice a dayPotential for systemicabsorption of drugand alteration ofcalcium homeostasisPotential skinirritation[4, 13, 149, 196]Topical calcipotriol– betamethasonedipropionate ointmentORCombination of superpotenttopical steroid andVitamin D3 analogueCombined mechanism of actionof topical corticosteroidsand Vitamin D3 analogues(as above)Applied one to two timesdailySame potential adverseeffects as topicalcorticosteroidsand Vitamin D3analogues (as above)Topical tacrolimus Calcineurin inhibitor,immunomodulator that inhibitsT-cell activation and cytokineproduction0.1% ointment twice a day Increased risk ofcutaneous herpesinfection; potentialfor systemicabsorption[13, 198–201]Imiquimod Reduces TGF-beta and PDGFlevels, increases IFN-gamma,IFN-alpha and TNF-alpha toinhibit fibrosisTopical 5% cream dailyapplied 3 days perweekAllergic reaction; mildskin irritation[13, 124, 197,202, 203]PhototherapiesAgent Action Dose ReferencesPsoralen and UVA (PUVA) Alters cytokine environment ofskin, reduces cutaneous T-cellactivity, affects Langerhans’cells, cutaneous macrophagesand keratinocyte function.Induces metalloproteasescausing increased collagenbreakdownOral 8-methoxypsoralen(25 mg/m2bodysurface area) given2 h before exposure toUVA , given two timesa week[13, 204]Bath PUVA Alters cytokine environment ofskin, enhances gene expressionof collagenase, reducesexpression of collagen anddecreases collagen cross-links1 mg/L 8-methoxypsoralenin warm water bath for15 min, then 0.2–4 mJ/cm2daily for 10 days,followed by bathPUVA once a week[13, 205]UV-A1 phototherapy Alters cytokine environment ofskin; induces apoptosis ofT-cells; decreases collagen typeI and III mRNA and increasesmatrix metalloproteasesHigh dose protocol:starting dose of 40–60J/cm2increasing to100 J/cm2three timesper week for 40–60treatments (Personalcommunication; HeidiJacobe, MD)[13, 140, 151, 206–210]Narrow band UVB(Nb UVB)Similar to broad band UVB, butminimizes burning and otherside effectsStarting dose 0.1–0.2 J/cm2Maximum dose1.3–1.5 J/cm2, givenfive times a week[15, 85](continued)
126 A.E. Gilliam and A.C. GilliamExtracorporealphotochemotherapyAlters leukocyte function, causesapoptosis of lymphocytes andactivation of dendritic cellsTwo consecutive therapiesper day at 2-weekintervals[155, 211]Photodynamic therapy(PDT) with visible lightAlters cytokine environment ofskin, induces MMP-1 andMMP-3 in dermal fibroblasts;induces keratinocyte cytokinealterations5-amino levulinic acid(ALA) 20% creamunder occlusion toone area of morpheafor 5 h. Treatedwith PhotoCureTMCureLight 1301;570–670 nm, 25 J⁄cm2at weekly intervals forsix treatments totalSystemic therapiesAgent Action Dose Adverse effects ReferencesCorticosteroids: Oraland IntravenousaReduces inflammation, usuallycombined with methotrexateOral prednisone:0.5–1 mg/kg/dayfor several weeks,followed by slow taperImmunosuppression,bruising,hypertension,hyperglycemia,avascular necrosisof bone[13, 85,212, 213]Intravenousmethylprednisolone:30 mg/kg/dose (up to1 g)×three consecutivedoses monthly for3–6 monthsMethotrexate, oralor subcutaneousaInhibits folate-dependent enzymesimportant to DNA, RNA andprotein synthesis; immunemodulation by altering serumcytokine levels15–25 mg/week or0.3–0.6 mg/kg/week;folic acid 1 mg/day isgiven concomitantlyElevated liver functiontests, stomatitis,fatigue, weight loss,nausea[85, 212–218]Oral calcitriol Inhibits growth of dermal fibroblasts,affects fibroblast differentiation,possible immunoregulatoryeffects on Th-cellsOral 0.50–1.25 mcg/day,adult doseHypercalcemia,cutaneoushypersensitivityreactions[13, 219, 220]Oral anti-malarial drugshydroxychloroquineDecreases Toll Like Receptorsignaling, limiting B cell anddendritic cell activation andmitigating inflammatory responses200 mg daily or twicedaily (adult)Gastrointestinaldiscomfort,headache, dizziness,ocular toxicity[13, 56]4–6 mg/kg/day (pediatric)Oral d-penicillamine Inhibits collagen cross-linking 125–250 mg/day or2–5 mg/kg/dayChanges in tastesensation, anemia,leukopenia, hyper-sensitivity reactionsOral cyclosporine Immunomodulator; inhibits Th-cellfunction3 mg/kg/day Immunosuppression,renal toxicity,hypertension,malignancy risk[216, 222]Thalidomide Immunomodulation and anti-inflammatory, reduces TNF-alpha production, promoting aTh1 response, alters integrins,inhibits angiogenesisImmunosuppression,somnolence,leukopenia, allergicreaction, peripheralneuropathy, birthdefectsMycophenolate mofetil Selective inhibitor of purine synthesisthat inhibits proliferation oflymphocytes, fibroblasts andsmooth muscle cellsOral 600–1,200 mg/m2/daytwice a dayGastrointestinaldiscomfort,immunosuppression,cytopeniasPlasmapheresis Causes T-cell apoptosis, altersT-cell and dendritic cellfunction, alters cytokine andgrowth factor environment[154, 223]aA common practice is to give monthly pulses of methylprednisolone intravenously in combination with oral or subcutaneously administeredmethotrexate followed by oral prednisone given in combination with methotrexatePhototherapiesAgent Action Dose ReferencesTable 12.3 (continued)
12712 Localized Forms of Sclerodermaphototherapy include erythema, sunburn, cutaneous photodamage, increased risk of skin carcinoma and premature ageing.The psoralens can cause gastrointestinal discomfort when taken orally.The number of treatments per week varies from three to five treatments per week for 20–40 treatments. Although UVA1is the preferred wavelength, it is not widely available, especially in the US. Therefore, most physicians rely on NbUVBtherapy in lieu of UVA1. Encouraging results were reported by Kreuter et al. , who demonstrated that although UVA1was significantly more effective in softening skin lesions of localized scleroderma, NbUVB produced remarkable improve-ment in skin lesions as well.Systemic Therapy. The most commonly used systemic therapies include corticosteroids, methotrexate, d-penicillamine, oralcalcitriol, and hydroxychloroquine. Guidelines of care for morphea describe these modalities [146, 147]. In general, treatmentwith the systemic agents is based on type of morphea, extent and location of disease, and likelihood of complications suchas disfigurement or functional disability without treatment [9, 15, 136, 148].An algorithm for therapy of the various types of morphea acute and chronic is presented below.Initial therapy. First line therapy for morphea is most often topical corticosteroids. For non-facial, well-localized, plaque-type skin lesions, observation is appropriate with the possible addition of super-potent topical steroids and/or topical calci-potriene, which has been demonstrated to soften skin lesions, especially when used under occlusion . Other treatmentmodalities include physical therapy techniques both for improving range of motion of affected limbs as well as stretchingexercises for contractures .Many other agents have been reported as successful in isolated case reports or small open label trials, but none haveproved to be uniformly efficacious in double-blind placebo-controlled trials if tested.Intermediate level treatment for morphea recalcitrant to first line therapies usually includes the use of oral minocy-cline, hydroxychloroquine, and/or phototherapy. Oral minocycline is not often used in the US to treat morphea but hasbeen used in Europe to treat Borrelia-associated disease . Most dermatologists rely on phototherapy with ultravio-let light as the “next step” beyond topical therapy for more widespread, rapidly spreading, or potentially disfiguringdisease.Aggressive treatment of morphea usually includes the use of D-penicillamine, oral calcitriol, and/or methotrexate incombination with corticosteroids, which is now becoming the treatment of choice for patients with severe disease thatthreatens function or disfigurement [84, 139, 151–153].There are other experimental therapies for severe disease which have been tried in a few patients and in small clinicaltrials. Data from long term follow-up and controlled studies of large numbers of patients are not available to date(Table 12.4).Extracorporeal photochemotherapy and plasmapheresis have been reported in case studies [• 154, 155].Anti-thymocyte globulin was effective in an individual with rapidly progressive pansclerotic morphea and accompanying•pancytopenia due to bone marrow aplasia. The treatment of marrow failure with anti-thymocyte globulin was thought toreverse the abnormal immune process .Mycophenolate mofetil is being used more commonly in routine practice to treat morphea patients. Success was reported•in arresting disease activity with minimal side effects in a group of pediatric patients who failed methotrexate and corti-costeroids .Imatinib, a tyrosine kinase inhibitor which interferes with TGF-beta and platelet derived growth factor signaling path-•ways, has also been reported as successful for one adult patient with therapy-resistant morphea .Surgical TherapiesLinear morphea can be extremely disfiguring, and often fails medical treatment. In certain cases, surgical excision and repaircan be considered once the disease activity has “burned out”. Reconstructive surgery with tissue expansion, grafting andscalp reduction of en coup de sabre has been used for disfiguring disease . Autologous fat and artificial bone grafts arealso used with some success [160–162]. Autologous fat transplantation using donor sites from the buttocks or abdomen wasstudied in a series of 20 individuals with stable linear morphea of the face (en coup de sabre). The authors found the pro-cedure more useful for atrophic scarring of morphea over the forehead than over the nose, cheeks or chin where fat survivalwas less . Successful arthrodesis and flap surgery were described in a case of severe linear morphea over an extremity. Other modalities include use of cosmetic fillers such as Alloderm , BoneSource , poly-l-Lactic acid andpolyethylene implants in facial asymmetry [166, 167].
12912 Localized Forms of SclerodermaSummaryIn summary, morphea or localized scleroderma is a complex cutaneous disorder with multiple heterogeneous subtypes.There is no reduced mortality, but significant morbidity occurs mainly in the linear forms. Morphea is considered to be anautoimmune disorder because of the presence of autoantibodies; it can be associated with other autoimmune disorders andrarely is familial. The pathophysiology is unknown. The triggers may be similar to scleroderma (vascular injury, abnormalimmune regulation, extracellular matrix dysregulation) in genetically susceptible individuals. There are additional clues topathophysiology in the variants of morphea induced by triggers in the environment such as radiation, trauma, ingestion ofcertain drugs, injection of foreign materials and infection. Like scleroderma therapy, therapy of morphea is difficult to evalu-ate because disease tends to resolve spontaneously. The workhorses of therapy include topical corticosteroids, phototherapy,and methotrexate +/−systemic corticosteroids. There are some new immunomodulatory biologic agents for morphea alsobeing tested in small clinical trials.Acknowledgment We appreciate the expertise of Geralyn Bodeker, MS AHP in the Palo Alto Medical Foundation Group library and her helpwith obtaining reference material.References1. Sung JJ, Chen TS, Gilliam AC, McCalmont TH, Gilliam AE. Clinical-histopathological correlations in juvenile localized scleroderma (JLS);a subset of children with hypopigmented JLS due to loss of epidermal melanocytes. J Am Acad Dermatol. 2011;65(2):364–73.2. Kakimoto CV, Victor Ross E, Uebelhoer NS. En coup de sabre presenting as a port-wine stain previously treated with pulsed dye laser.Dermatol Surg. 2009;35(1):165–7.3. Nijhawan RI, Bard S, Blyumin M, Smidt AC, Chamlin SL, Connelly EA. Early localized morphea mimicking an acquired port-wine stain.J Am Acad Dermatol. 2011;64(4):779–82.4. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg. 1999;18(3):210–25.5. Hawk A, English 3rd JC. Localized and systemic scleroderma. Semin Cutan Med Surg. 2001;20(1):27–37.6. Strober BE. Generalized morphea. Dermatol Online J. 2003;9(4):24.7. Weibel L, Harper JI, Howell KJ. Morphea (localized scleroderma). J Pediatr. 2007;150(5):560.8. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger Jr TA, Lehman TJ, et al. The Pediatric Rheumatology European Society/AmericanCollege of Rheumatology/European League against rheumatism provisional classification criteria for juvenile systemic sclerosis. ArthritisRheum. 2007;57(2):203–12.9. Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008;20(5):601–7.10. Kaplan MJ. Localized fibrosing disorders – Linear Scleroderma, morphea, and regional fibrosis 2008. eMedicine. http://emedicine.medscape.com/article/334939.11. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a reviewof 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.12. Hansen CB, Callen JP. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther. 2010;23(4):341–9.13. Nguyen JV, Werth VP, Fett M. Morphea. eMedicine. http://emedicine.medscape.com/article/1065782-overview, editor. 2010.14. Saxton-Daniels S, Jacobe HT. An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010;146(9):1044–5.15. Vilela FA, Carneiro S, Ramos-e-Silva M. Treatment of morphea or localized scleroderma: review of the literature. J Drugs Dermatol. 2010;9(10):1213–9.16. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am AcadDermatol. 2007;56(2):257–63.17. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–76.18. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in OlmstedCounty 1960–1993. J Rheumatol. 1997;24(1):73–80.19. Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratoryinvestigations on 239 cases. Eur J Dermatol. 2003;13(2):171–6.20. Zulian F, Athreya BH, Laxer R, Nelson AM, de Oliveira SK Feitosa, Punaro MG, et al. Juvenile localized scleroderma: clinical and epide-miological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20.21. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol.2008;59(3):385–96.22. Toledano C, Rabhi S, Kettaneh A, Fabre B, Fardet L, Tiev KP, et al. Localized scleroderma: a series of 52 patients. Eur J Intern Med. 2009;20(3):331–6.23. Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F. Localized severe scleroderma: a retrospective study of 26 pediatric patients.Pediatr Dermatol. 2010;27(5):476–80.24. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK andIreland. Arthritis Care Res (Hoboken). 2010;62(2):213–8.
130 A.E. Gilliam and A.C. Gilliam25. Paller AS. Piecing together the puzzle of cutaneous mosaicism. J Clin Invest. 2004;114(10):1407–9.26. Orzechowski NM, Davis DM, Mason 3rd TG, Crowson CS, Reed AM. Health-related quality of life in children and adolescents with juvenilelocalized scleroderma. Rheumatology (Oxford). 2009;48(6):670–2.27. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. ArthritisRheum. 2005;52(9):2873–81.28. Barrera Vigo MV, Torrelo A, Hernandez A, Gonzalez G. Linear morphoea with spontaneous fractures. Br J Dermatol. 2008;158(4):852–3.29. Bockle BC, Willeit J, Freund M, Sepp NT. Neurological picture. Unexplained muscle atrophy as the unique preceding symptom of bilaterallinear morphea. J Neurol Neurosurg Psychiatry. 2009;80(3):310–1.30. Lehman AM, Patel MS. Childhood-onset hemiatrophy caused by unilateral morphea. Clin Dysmorphol. 2009;18(4):213–4.31. Muroi E, Ogawa F, Yamaoka T, Sueyoshi F, Sato S. Case of localized scleroderma associated with osteomyelitis. J Dermatol. 2010;37(1):81–4.32. Dobbie H, Lanham J, Unwin R. Morphea presenting as widespread oedema. J R Soc Med. 2002;95(9):459–60.33. Fiala KH, Wells MJ, Mullinax KA, Stetson CL, Paulger BR. Linear morphea presenting as acquired unilateral edema. Pediatr Dermatol.2007;24(2):147–50.34. Voermans NC, Pillen S, de Jong EM, Creemers MC, Lammens M, van Alfen N. Morphea profunda presenting as a neuromuscular mimic. J ClinNeuromuscul Dis. 2008;9(4):407–14.35. Petrov I, Gantcheva M, Miteva L, Vassileva S, Pramatarov K. Lower lip squamous cell carcinoma in disabling pansclerotic morphea ofchildhood. Pediatr Dermatol. 2009;26(1):59–61.36. Chiang KL, Chang KP, Wong TT, Hsu TR. Linear scleroderma “en coup de sabre”: initial presentation as intractable partial seizures in achild. Pediatr Neonatol. 2009;50(6):294–8.37. Rigante D, Battaglia D, Contaldo I, La Torraca I, Avallone L, Gaspari S, et al. Longstanding epileptic encephalopathy and linear localizedscleroderma: two distinct pathologic processes in an adolescent. Rheumatol Int. 2008;28(9):925–9.38. Menascu S, Padeh S, Hoffman C, Ben-Zeev B. Parry-Romberg syndrome presenting as status migrainosus. Pediatr Neurol. 2009;40(4):321–3.39. Duyff RF, Vos J. A “scar” and epilepsy: coup de sabre. J Neurol Neurosurg Psychiatry. 1998;65(4):568.40. Sartori S, Martini G, Calderone M, Patrizi A, Gobbi G, Zulian F. Severe epilepsy preceding by four months the onset of scleroderma en coupde sabre. Clin Exp Rheumatol. 2009;27(3 Suppl 54):64–7.41. Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology.2008;71(19):1538–45.42. Moseley BD, Burrus TM, Mason TG, Shin C. Neurological picture. Contralateral cutaneous and MRI findings in a patient with Parry-Romberg syndrome. J Neurol Neurosurg Psychiatry.. 2010;81(12):1400–1.43. Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, et al. Ocular involvement in children with localised scleroderma:a multi-centre study. Br J Ophthalmol. 2007;91(10):1311–4.44. Kasap B, Soylu A, Turkmen M, Goktay Y, Sarioglu S, Ozturk C, et al. Juvenile linear scleroderma with unique forms of renal involvement.Pediatr Nephrol. 2009;24(10):2041–5.45. Wozniak J, Dabrowski R, Luczak D, Kwiatkowska M, Musiej-Nowakowska E, Kowalik I, et al. Evaluation of heart rhythm variability andarrhythmia in children with systemic and localized scleroderma. J Rheumatol. 2009;36(1):191–6.46. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol. 1999;455:85–92.47. Callen JP. Collagen vascular diseases. J Am Acad Dermatol. 2004;51(3):427–39.48. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol.2008;35(4):650–7.49. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol. 2006;24(5):374–92.50. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis. 2003;62(8):771–4.51. Tomimura S, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E, et al. Autoantibodies against matrix metalloproteinase-1 in patients with local-ized scleroderma. J Dermatol Sci. 2008;52(1):47–54.52. Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, et al. Elevated serum BAFF levels in patients with localizedscleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol. 2007;16(2):87–93.53. Alimova E, Farhi D, Plantier F, Carlotti A, Gorin I, Mouthon L, et al. Morphoea (localized scleroderma): baseline body surface involvementand antinuclear antibody may have a prognostic value. Clin Exp Dermatol. 2009;34(7):e491–2.54. Ohmatsu H, Tada Y, Yazawa N, Kadono T, Tamaki K. Generalized morphea positive for anticentromere antibody. Eur J Dermatol. 2008;18(6):718–9.55. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signa-tures of scleroderma skin. PLoS One. 2008;3(7):e2696.56. Brownell I, Soter NA, Franks Jr AG. Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultravioletB therapy. Dermatol Online J. 2007;13(1):11.57. Pham CM, Browning JC. Morphea affecting a father and son. Pediatr Dermatol. 2010;27(5):536–7.58. Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions.Arthritis Rheum. 2009;60(3):661–8.59. Hayashi M, Ichiki Y, Kitajima Y. Coexistence of recurrent generalized morphea and systemic sclerosis. Acta Derm Venereol. 2009;89(3):329–30.60. Julia M, Mascaro Jr JM, Guilabert A, Navarra E, Ferrando J, Herrero C. Sclerodermiform linear lupus erythematosus: a distinct entity orcoexistence of two autoimmune diseases? J Am Acad Dermatol. 2008;58(4):665–7.61. Ko JY, Kim YS, Lee CW. Multifocal lesions of morphoea in a patient with systemic lupus erythematosus. Clin Exp Dermatol. 2009;34(8):e676–9.62. Firoz EF, Kamino H, Lehman TJ, Orlow SJ. Morphea, diabetes mellitus type I, and celiac disease: case report and review of the literature.Pediatr Dermatol. 2010;27(1):48–52.63. Dervis E, Acbay O, Barut G, Karaoglu A, Ersoy L. Association of vitiligo, morphea, and Hashimoto’s thyroiditis. Int J Dermatol. 2004;43(3):236–7.
13112 Localized Forms of Scleroderma64. Hiremath NC, Madan Mohan NT, Srinivas C, Sangolli PM, Srinivas K, Vrushali VD. Juvenile localized scleroderma with autoimmunethyroid disorder. Indian J Dermatol. 2010;55(3):308–9.65. Bonifati C, Impara G, Morrone A, Pietrangeli A, Carducci M. Simultaneous occurrence of linear scleroderma and homolateral segmentalvitiligo. J Eur Acad Dermatol Venereol. 2006;20(1):63–5.66. Bowen C, Kobayashi TT. What is your diagnosis? Segmental vitiligo and en coup de sabre. Cutis. 2010;85(5):230, 237–8.67. Hasegawa M, Fujimoto M, Hayakawa I, Matsushita T, Nishijima C, Yamazaki M, et al. Anti-phosphatidylserine-prothrombin complex anti-bodies in patients with localized scleroderma. Clin Exp Rheumatol. 2006;24(1):19–24.68. Morita A, Tsuji T. Necrotizing vasculitis in a patient with generalized morphea. J Am Acad Dermatol. 2001;45(6 Suppl):S215–7.69. Lane TK, Cheung J, Schaffer JV. Parry-Romberg syndrome with coexistent morphea. Dermatol Online J. 2008;14(10):21.70. Slimani S, Hounas F, Ladjouze-Rezig A. Multiple linear sclerodermas with a diffuse Parry-Romberg syndrome. Joint Bone Spine.2009;76(1):114–6.71. Saleh Z, Arayssi T, Saleh Z, Ghosn S. Superficial morphea: 20-year follow up in a patient with concomitant psoriasis vulgaris. J CutanPathol. 2009;36(10):1105–8.72. Munoz-Perez MA, Camacho F. Lichen planopilaris and scleroderma en coup de sabre. J Eur Acad Dermatol Venereol. 2002;16(5):542–4.73. Kim DH, Lee KR, Kim TY, Yoon MS. Coexistence of lichen sclerosus with morphoea showing bilateral symmetry. Clin Exp Dermatol.2009;34(7):e416–8.74. Sinha A, Natarajan S. Linear morphea, nevus comedonicus, and lichen striatus in a 5-year-old girl. Pediatr Dermatol. 2011;28(1):72–74.75. Chappell JA, Burkemper NM, Frater JL, Hurley MY. Cutaneous Rosai-Dorfman disease and morphea: coincidence or association? AmJ Dermatopathol. 2009;31(5):487–9.76. Gilmour TK, Wilkinson B, Breit SN, Kossard S. Analysis of dendritic cell populations using a revised histological staging of morphoea. BrJ Dermatol. 2000;143(6):1183–92.77. Saleh Z, Abbas O, Dahdah MJ, Kibbi AG, Zaynoun S, Ghosn S. Atrophoderma of Pasini and Pierini: a clinical and histopathological study.J Cutan Pathol. 2008;35(12):1108–14.78. Walters R, Pulitzer M, Kamino H. Elastic fiber pattern in scleroderma/morphea. J Cutan Pathol. 2009;36(9):952–7.79. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissuerepair. Mol Med. 1994;1(1):71–81.80. Barth PJ, Westhoff CC. CD34+ fibrocytes: morphology, histogenesis and function. Curr Stem Cell Res Ther. 2007;2(3):221–7.81. Aiba S, Tabata N, Ohtani H, Tagami H. CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. ArchDermatol. 1994;130(5):593–7.82. Skobieranda K, Helm KF. Decreased expression of the human progenitor cell antigen (CD34) in morphea. Am J Dermatopathol. 1995;17(5):471–5.83. McNiff JM, Glusac EJ, Lazova RZ, Carroll CB. Morphea limited to the superficial reticular dermis: an underrecognized histologic phenom-enon. Am J Dermatopathol. 1999;21(4):315–9.84. Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effectin CD34-positive dendritic cells. J Am Acad Dermatol. 2001;45(5):697–9.85. Kreuter A, Hyun J, Skrygan M, Sommer A, Tomi NS, Breuckmann F, et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 geneexpression in localized scleroderma. Arch Dermatol Res. 2006;298(6):265–72.86. Xie Y, Zhang X, Wakasugi S, Makino T, Inoue Y, Ihn H. Immunohistochemical characterization of the cellular infiltrate in localized sclero-derma. Int J Dermatol. 2008;47(5):438–42.87. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient withlocalized scleroderma. Exp Dermatol. 2009;18(8):727–9.88. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of trans-forming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis,morphea, and Raynaud’s phenomenon. Arthritis Rheum. 1994;37(2):278–88.89. Fawzi MM, Tawfik SO, Eissa AM, El-Komy MH, Abdel-Halim MR, Shaker OG. Expression of insulin-like growth factor-I in lesional andnon-lesional skin of patients with morphoea. Br J Dermatol. 2008;159(1):86–90.90. Ihn H, Fujimoto M, Sato S, Kikuchi K, Igarashi A, Soma Y, et al. Increased levels of circulating intercellular adhesion molecule-1 in patientswith localized scleroderma. J Am Acad Dermatol. 1994;31(4):591–5.91. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patientswith localized scleroderma. Arch Dermatol Res. 1995;287(2):193–7.92. Uziel Y, Feldman BM, Krafchik BR, Laxer RM, Yeung RS. Increased serum levels of TGFbeta1 in children with localized scleroderma.Pediatr Rheumatol Online J. 2007;5:22.93. Schaffer JV, Carroll C, Dvoretsky I, Huether MJ, Girardi M. Postirradiation morphea of the breast presentation of two cases and review ofthe literature. Dermatology. 2000;200(1):67–71.94. Shetty G, Lewis F, Thrush S. Morphea of the breast: case reports and review of literature. Breast J. 2007;13(3):302–4.95. Cheah NL, Wong DW, Chetiyawardana AD. Radiation-induced morphea of the breast: a case report. J Med Case Reports. 2008;2:136.96. Walsh N, Rheaume D, Barnes P, Tremaine R, Reardon M. Postirradiation morphea: an underrecognized complication of treatment for breastcancer. Hum Pathol. 2008;39(11):1680–8.97. Mosterd K, Winnepenninckx V, Vermeulen A, van Neer PA, van Neer FJ, Frank J. Morphea following surgery and radiotherapy: an evolvingproblem. J Eur Acad Dermatol Venereol. 2009;23(9):1099–101.98. Akay BN, Sanli H, Heper AO. Postirradiation linear morphoea. Clin Exp Dermatol. 2010;35(4):e106–8.99. Clark CJ, Wechter D. Morphea of the breast – an uncommon cause of breast erythema. Am J Surg. 2010;200(1):173–6.100. de Giorgi V, Santi R, Grazzini M, Papi F, Gori A, Rossari S, et al. Synchronous angiosarcoma, melanoma and morphea of the breast skin14 years after radiotherapy for mammary carcinoma. Acta Derm Venereol. 2010;90(3):283–6.101. Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beamradiation: radiation port scleroderma. J Am Acad Dermatol. 1996;35(6):923–7.
132 A.E. Gilliam and A.C. Gilliam102. Sahn EE, Garen PD, Silver RM, Maize JC. Scleroderma following augmentation mammoplasty. Report of a case and review of the literature.Arch Dermatol. 1990;126(9):1198–202.103. Ozgur F, Kayikcioglu A. Linear scleroderma after rhinoplasty. Plast Reconstr Surg. 1998;101(2):539–40.104. McClelland M, VanLoock JS, Patterson JW, Greer KE. Radiation-induced morphea occurring after fluoroscopy. J Am Acad Dermatol.2002;47(6):962–4.105. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review ofthe literature. J Am Acad Dermatol. 2008;59(1):125–9.106. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, et al. Double-blind, placebo-controlled study of intralesionalinterferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol. 1997;36(3 Pt 1):433–5.107. Obermoser G, Pfausler BE, Linder DM, Sepp NT. Scleroderma en coup de sabre with central nervous system and ophthalmologic involve-ment: treatment of ocular symptoms with interferon gamma. J Am Acad Dermatol. 2003;49(3):543–6.108. Hugle T, Gratzl S, Daikeler T, Frey D, Tyndall A, Walker UA. Sclerosing skin disorders in association with multiple sclerosis. Coincidence,underlying autoimmune pathology or interferon induced? Ann Rheum Dis. 2009;68(1):47–50.109. Beretta L, Caronni M, Vanoli M, Scorza R. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol.2002;147(2):385–6.110. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronicviral hepatitis. Clin Exp Rheumatol. 2004;22(5):625–8.111. Airo P, Scarsi M, Rossi M, Mondini M. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int.2008;28(7):703–7.112. Bakst R, Kovarik C, Werth VP. A case of localized scleroderma in a sculptor and his wife. J Clin Rheumatol. 2009;15(8):399–401.113. Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol. 2007;157(6):1189–98.114. Weber K. Is juvenile localized scleroderma related to Lyme borreliosis? J Am Acad Dermatol. 2009;61(5):901.115. Prinz JC, Kutasi Z, Weisenseel P, Poto L, Battyani Z, Ruzicka T. “Borrelia-associated early-onset morphea”: a particular type of sclerodermain childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J Am AcadDermatol. 2009;60(2):248–55.116. Zollinger T, Mertz KD, Schmid M, Schmitt A, Pfaltz M, Kempf W. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J Cutan Pathol. 2010;37(5):571–7.117. Carlesimo M, Abruzzese C, Narcisi A, La Pietra M, Fardella A, Noto S, et al. Acrodermatitis chronic atrophicans and morphea. Eur J Dermatol.2010;20(3):405–7.118. Gilliam AC, Scleroderma. In Nickoloff B and Nestle F, eds. Current Directions in Autoimmunity: Dermatologic Autoimmunity, KargerPress, Basel, 2008:258–79. Chicago/London: Karger.119. Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician globalassessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12):2819–29.120. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger Jr TA. Development and initial validation of the localized scleroderma skin damage indexand physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2010;49(2):373–81.121. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment ofinterobserver variability in 3 independent studies. J Rheumatol. 1993;20(11):1892–6.122. Zachariae H, Bjerring P, Halkier-Sorensen L, Heickendorff L, Sondergaard K. Skin scoring in systemic sclerosis: a modification – relationsto subtypes and the aminoterminal propeptide of type III procollagen (PIIINP). Acta Derm Venereol. 1994;74(6):444–6.123. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Reliability of two methods to assess morphea: skin scoring and the use of adurometer. J Am Acad Dermatol. 1997;37(5 Pt 1):793–6.124. Campione E, Paterno EJ, Diluvio L, Orlandi A, Bianchi L, Chimenti S. Localized morphea treated with imiquimod 5% and dermoscopicassessment of effectiveness. J Dermatolog Treat. 2009;20(1):10–3.125. Zulian F, Meneghesso D, Grisan E, Vittadello F, Belloni Fortina A, Pigozzi B, et al. A new computerized method for the assessment of skinlesions in localized scleroderma. Rheumatology (Oxford). 2007;46(5):856–60.126. Cosnes A, Anglade MC, Revuz J, Radier C. Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma. Br J Dermatol.2003;148(4):724–9.127. Bendeck SE, Jacobe HT. Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the useof radiologic techniques to assess skin disease. Dermatol Ther. 2007;20(2):86–92.128. Li SC, Liebling MS. The use of Doppler ultrasound to evaluate lesions of localized scleroderma. Curr Rheumatol Rep. 2009;11(3):205–11.129. Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O’Neil KM. Treatment of pediatric localized scleroderma: results of a surveyof North American pediatric rheumatologists. J Rheumatol. 2010;37(1):175–81.130. Horger M, Fierlbeck G, Kuemmerle-Deschner J, Tzaribachev N, Wehrmann M, Claussen CD, et al. MRI findings in deep and generalizedmorphea (localized scleroderma). AJR Am J Roentgenol.. 2008;190(1):32–9.131. Martini G, Murray KJ, Howell KJ, Harper J, Atherton D, Woo P, et al. Juvenile-onset localized scleroderma activity detection by infraredthermography. Rheumatology (Oxford). 2002;41(10):1178–82.132. Moore TL, Vij S, Murray AK, Bhushan M, Griffiths CE, Herrick AL. Pilot study of dual-wavelength (532 and 633 nm) laser Doppler imag-ing and infrared thermography of morphoea. Br J Dermatol. 2009;160(4):864–7.133. Howell KJ, Lavorato A, Visentin MT, Smith RE, Schaefer G, Jones CD, et al. Validation of a protocol for the assessment of skin temperatureand blood flow in childhood localised scleroderma. Skin Res Technol. 2009;15(3):346–56.134. Woo P. Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol. 2009;21(5):552–7.135. Callen JP. New and emerging therapies for collagen-vascular diseases. Dermatol Clin. 2000;18(1):139–46.136. Kawashima H, Watanabe C, Kashiwagi Y, Sato S, Ioi H, Sasamoto M, et al. Therapy of childhood generalized morphea: case reports andreviews of the literature of Japanese cases. Pediatr Int. 2006;48(3):342–5.
13312 Localized Forms of Scleroderma137. Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. Systemic and localized scleroderma in children: current and future treatment options.Paediatr Drugs. 2006;8(2):85–97.138. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.139. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized sclero-derma and systemic sclerosis. Rheumatology (Oxford). 2009;48(3):213–21.140. Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systematicreview. J Am Acad Dermatol. 2008;59(6):1017–30.141. Bielsa I, Ariza A. Deep morphea. Semin Cutan Med Surg. 2007;26(2):90–5.142. Silny W, Osmola-Mankowska A, Czarnecka-Operacz M, Zaba R, Danczak-Pazdrowska A, Marciniak A. Eosinophilic fascitis: a report oftwo cases treated with ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed. 2009;25(6):325–7.143. Karrer S, Abels C, Landthaler M, Szeimies RM. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol. 2000;80(1):26–7.144. Batchelor R, Lamb S, Goulden V, Stables G, Goodfield M, Merchant W. Photodynamic therapy for the treatment of morphoea. Clin ExpDermatol. 2008;33(5):661–3.145. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-doseUVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–7.146. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for scleroderma and sclerodermoiddisorders. American Academy of Dermatology. J Am Acad Dermatol.. 1996;35(4):609–14.147. Kreuter A, Krieg T, Worm M, Wenzel J, Gambichler T, Kuhn A, et al. AWMF Guideline no. 013/066. Diagnosis and therapy of circum-scribed scleroderma. J Dtsch Dermatol Ges. 2009;7(Suppl 6):S1–14.148. Kreuter A, Altmeyer P, Gambichler T. Treatment of localized scleroderma depends on the clinical subtype. Br J Dermatol. 2007;156(6):1363–5.149. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol.1998;39(2 Pt 1):211–5.150. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme dis-ease spirochete Borrelia burgdorferi. J Infect Dis. 2009;199(9):1379–88.151. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, et al. High-dose UVA1 radiation therapy for localized sclero-derma. J Am Acad Dermatol. 1997;36(6 Pt 1):938–44.152. El-Mofty M, Mostafa W, Esmat S, Youssef R, Bousseila M, Nagi N, et al. Suggested mechanisms of action of UVA phototherapy in morphea:a molecular study. Photodermatol Photoimmunol Photomed. 2004;20(2):93–100.153. Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y. New therapeutic strategies for systemic sclerosis – a critical analysis of the literature.Clin Dev Immunol. 2005;12(3):165–73.154. Melani L, Caproni M, Cardinali C, Antiga E, Bernacchi E, Schincaglia E, et al. A case of nodular scleroderma. J Dermatol. 2005;32(12):1028–31.155. Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol. 2009;145(2):127–30.156. Song P, Gocke C, Wigley FM, Boin F. Resolution of pansclerotic morphea after treatment with antithymocyte globulin. Nat Rev Rheumatol.2009;5(9):513–6.157. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenilelocalized scleroderma with mycophenolate mofetil. Rheumatology (Oxford). 2009;48(11):1410–3.158. Moinzadeh P, Krieg T, Hunzelmann N. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol.2010;63(5):e102–4.159. Palmero ML, Uziel Y, Laxer RM, Forrest CR, Pope E. En coup de sabre scleroderma and parry-romberg syndrome in adolescents: surgicaloptions and patient-related outcomes. J Rheumatol. 2010;37(10):2174–9.160. Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coupde sabre by en bloc autologous dermal fat graft. Dermatol Surg. 2000;26(8):793–7.161. Roh MR, Jung JY, Chung KY. Autologous fat transplantation for depressed linear scleroderma-induced facial atrophic scars. Dermatol Surg.2008;34(12):1659–65.162. Eguchi T, Harii K, Sugawara Y. Repair of a large “coup de sabre” with soft-tissue expansion and artificial bone graft. Ann Plast Surg. 1999;42(2):207–10.163. Nguyen XH, Hansen R, Valencia F. Severe ankle deformity secondary to pansclerotic morphea in a 9-year-old girl: correction involvingarthrodesis and free flap coverage. Pediatr Dermatol. 2002;19(6):560–3.164. Robitschek J, Wang D, Hall D. Treatment of linear scleroderma “en coup de sabre” with AlloDerm tissue matrix. Otolaryngol Head NeckSurg. 2008;138(4):540–1.165. Hwang DY, Paik HW, Byeon JH. Correction of facial linear scleroderma ‘coup de sabre’ with BoneSource. J Plast Reconstr Aesthet Surg.2009;62(2):e25–8.166. Copcu E. Treatment of coup de sabre deformity with porous polyethylene implant. Plast Reconstr Surg. 2004;113(2):758–9.167. Onesti MG, Troccola A, Scuderi N. Volumetric correction using poly-L-lactic acid in facial asymmetry: Parry Romberg syndrome and scle-roderma. Dermatol Surg. 2009;35(9):1368–75.168. Kauer F, Simon JC, Sticherling M. Nodular morphea. Dermatology. 2009;218(1):63–6.169. Jacobson L, Palazij R, Jaworsky C. Superficial morphea. J Am Acad Dermatol. 2003;49(2):323–5.170. Srinivasan SK, DiMaio D. Superficial morphea in a man. J Am Acad Dermatol. 2004;51(5 Suppl):S156–8.171. Khelifa E, Masouye I, Chavaz P, Hauser H, Grillet JP, Borradori L. Primary atrophic solitary morphea profunda. Dermatology. 2008;217(3):207–10.172. Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opin Rheumatol. 1997;9(6):562–70.
134 A.E. Gilliam and A.C. Gilliam173. Daniel RS, Lavery S, Maize Jr JC, Brown AN, Bolster MB. Unilateral eosinophilic fasciitis: an under-recognized subtype? J Clin Rheumatol..2009;15(5):247–9.174. Moulin C, Cavailhes A, Balme B, Skowron F. Morphoea-like plaques revealing an eosinophilic (Shulman) fasciitis. Clin Exp Dermatol.2009;34(8):e851–3.175. Forsea AM, Cretu AN, Ionescu R, Giurcaneanu C. Disabling pansclerotic morphea of childhood – unusual case and management challenges.J Med Life. 2008;1(3):348–54.176. Kreft B, Wohlrab J, Radant K, Danz B, Marsch WC, Fiedler E. Unrecognized radiation-induced localized scleroderma: a cause of postopera-tive wound-healing disorder. Clin Exp Dermatol. 2009;34(7):e383–4.177. Mattozzi C, Richetta AG, Cantisani C, Giancristoforo S, D’Epiro S, Gonzalez Serva A, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. Eur J Dermatol. 2010;20(3):400–1.178. Leshin B, Piette WW, Caplan RM. Morphea after bromocriptine therapy. Int J Dermatol. 1989;28(3):177–9.179. Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA. Docetaxel (Taxotere) associated scleroderma-like changes of the lowerextremities. A report of three cases. Cancer.. 1995;76(1):110–5.180. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol.2001;19(2):197–200.181. Kraigher O, Brenner S, Tur E. Anti-double-stranded DNA-positive unilateral generalized morphea in an adult, possibly exacerbated byibuprofen. Arch Dermatol. 2009;145(7):844–6.182. Freundlich B, Werth VP, Rook AH, O’Connor CR, Schumacher HR, Leyden JJ, et al. L-tryptophan ingestion associated with eosinophilicfasciitis but not progressive systemic sclerosis. Ann Intern Med. 1990;112(10):758–62.183. Feroze K, Venkitakrishnan S, Manoj J. L-tryptophan and scleroderma: significance of nutritional supplements containing L-tryptophan.J Postgrad Med. 2008;54(3):235–6.184. Gerceker Turk B, Urkmez A, Kilinc Karaarslan I, Ertam I, Kandiloglu G, Dereli T. Unilateral generalized morphoea: could vibration be astimulating factor? Clin Exp Dermatol. 2010;35(4):e165–6.185. Kluger N, Mathelier-Fusade P, Moguelet P. Scleroderma-like reaction restricted to the red parts of a tattoo. Acta Derm Venereol. 2009;89(1):95–6.186. Torrelo A, Suarez J, Colmenero I, Azorin D, Perera A, Zambrano A. Deep morphea after vaccination in two young children. Pediatr Dermatol.2006;23(5):484–7.187. El S-C, Poelt P, Aberer W, Aberer E. Progressive circumscribed sclerosis – a novel side-effect of immunotherapy with aluminium-adsorbedallergen extracts. Allergy. 2009;64(6):965–7.188. Ueda T, Niiyama S, Amoh Y, Katsuoka K. Linear scleroderma after contusion and injection of mepivacaine hydrochloride. Dermatol OnlineJ. 2010;16(5):11.189. Mihas AA, Abou-Assi SG, Heuman DM. Cutae morphea associated with chronic hepatitis C. J Hepatol. 2003;39(3):458–9.190. Badri T, El Euch D, Maamouri N, Ben Tekaya N, Ben Osman Dhahri A. Generalized cutaneous morphea in a patient with post-hepatitis Ccirrhosis. Acta Dermatovenerol Alp Panonica Adriat. 2007;16(1):40–1.191. Benmously Mlika R, Kenani N, Badri T, Hammami H, Hichri J, Haouet S, et al. Morphea profunda in a young infant after hepatitis B vac-cination. J Am Acad Dermatol. 2010;63(6):1111–2.192. Soylu S, Gul U, Gonul M, Kilic A, Cakmak SK, Demiriz M. An uncommon presentation of the co-existence of morphea and vitiligo in apatient with chronic hepatitis B virus infection: is there a possible association with autoimmunity? Am J Clin Dermatol. 2009;10(5):336–8.193. Telakis E, Nikolaou A. Localized scleroderma (morphea) in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21(4):486.194. Warner M, Camisa C, editors. Topical corticosteroids. Philadelphia: WB Saunders; 2001.195. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol. 2002;138(1):99–105.196. Tay YK. Topical calcipotriol ointment in the treatment of morphea. J Dermatolog Treat. 2003;14(4):219–21.197. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol. 2005;153(4):815–20.198. Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol. 2003;13(6):590–2.199. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol. 2005;152(1):180–2.200. Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, et al. Topical tacrolimus 0.1% ointment in thetreatment of localized scleroderma. An open label clinical and histological study. J Dermatol. 2008;35(11):712–8.201. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181–7.202. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg. 2004;8(3):166–9.203. Namazi MR. Imiquimod: a potential weapon against morphea and fibromatoses. J Drugs Dermatol. 2004;3(4):362–3.204. Usmani N, Murphy A, Veale D, Goulden V, Goodfield M. Photochemotherapy for localized morphoea: effect on clinical and molecularmarkers. Clin Exp Dermatol. 2008;33(6):698–704.205. Uchiyama M, Okubo Y, Kawashima H, Yamamoto K, Mitsuhashi Y, Tsuboi R. Case of localized scleroderma successfully treated with bathpsoralen and ultraviolet A therapy. J Dermatol. 2010;37(1):75–80.206. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, Lininger J, Reuther T, Kerscher M, et al. Effects of low dose ultraviolet A-1 photo-therapy on morphea. Photodermatol Photoimmunol Photomed. 2001;17(4):149–55.207. El-Mofty M, Mostafa W, El-Darouty M, Bosseila M, Nada H, Yousef R, et al. Different low doses of broad-band UVA in the treatment ofmorphea and systemic sclerosis. Photodermatol Photoimmunol Photomed. 2004;20(3):148–56.208. Jacobe HT, Cayce R, Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br JDermatol. 2008;159(3):691–6.209. Ozdemir M, Engin B, Toy H, Mevlitoglu I. Treatment of plaque-type localized scleroderma with retinoic acid and ultraviolet A plus thephotosensitizer psoralen: a case series. J Eur Acad Dermatol Venereol. 2008;22(4):519–21.
13512 Localized Forms of Scleroderma210. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized sclero-derma: a retrospective and prospective study. Br J Dermatol. 2010;162(2):445–7.211. Schlaak M, Friedlein H, Kauer F, Renner R, Rogalski C, Simon JC. Successful therapy of a patient with therapy recalcitrant generalizedbullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2008;22(5):631–3.212. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. JPediatr. 2000;136(1):91–5.213. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment oflocalized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5):1013–20.214. Seyger MM, van den Hoogen FH, van Vlijmen-Willems IM, van de Kerkhof PC, de Jong EM. Localized and systemic scleroderma showdifferent histological responses to methotrexate therapy. J Pathol. 2001;193(4):511–6.215. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am AcadDermatol. 1998;39(2 Pt 1):220–5.216. Crespo MP, Mas IB, Diaz JM, Costa AL, Nortes IB. Rapid response to cyclosporine and maintenance with methotrexate in linear sclero-derma in a young girl. Pediatr Dermatol. 2009;26(1):118–20.217. Jessop S, Whitelaw D. Methotrexate for sclerotic skin disorders: no evidence for effectiveness. Br J Dermatol. 2009;161(5):1205.218. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatmentwith methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160(5):1075–82.219. Humbert P, Aubin F, Dupond JL, Delaporte E. Oral calcitriol as a new therapeutic agent in localized and systemic scleroderma. ArchDermatol. 1995;131(7):850–1.220. Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, et al. Double-blind, placebo-controlled studyof oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43(6):1017–23.221. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol. 1990;126(5):609–12.222. Strauss RM, Bhushan M, Goodfield MJ. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol. 2004;150(4):790–2.223. Wach F, Ullrich H, Schmitz G, Landthaler M, Hein R. Treatment of severe localized scleroderma by plasmapheresis – report of three cases.Br J Dermatol. 1995;133(4):605–9.224. Bibi Y, Gottlieb AB. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and local-ized sclerosis. J Am Acad Dermatol. 2008;59(4):654–8.225. Diab M, Coloe JR, Magro C, Bechtel MA. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol. 2010;146(6):601–4.226. Reiter N, El-Shabrawi L, Leinweber B, Aberer E. Subcutaneous morphea with dystrophic calcification with response to ceftriaxone treat-ment. J Am Acad Dermatol. 2010;63(2):e53–5.227. Roldan R, Morote G, Castro Mdel C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneousulceration in disabling pansclerotic morphea in children. J Rheumatol. 2006;33(12):2538–40.228. Brocard A, Quereux G, Moyse D, Dreno B. Localized scleroderma and zinc: a pilot study. Eur J Dermatol. 2010;20(2):172–4.229. Le EN, Freischlag JA, Christo PJ, Chhabra A, Wigley FM. Thoracic outlet syndrome secondary to localized scleroderma treated with botu-linum toxin injection. Arthritis Care Res. 2010;62(3):430–3.